🗞️ Why in News Indian Express editorial analyses the broader implications of the Semaglutide (Ozempic/Wegovy) patent expiry on March 20, 2026, with approximately 50 generic brands entering the Indian market — arguing that India must match drug access with regulatory vigilance to maintain its credibility as the “pharmacy of the world.”
India’s Generics Prowess — The Global Context
India is often called the “pharmacy of the world” — and the numbers justify the title:
| Metric | Value |
|---|---|
| Share of global generic production (by volume) | 20% |
| Global rank by volume | 3rd |
| Global rank by value | 14th |
| Countries supplied | 200+ |
| US generic drug market share | India supplies ~40% of US generic demand |
| Africa’s drug supply | India supplies ~60-80% of anti-retroviral drugs for HIV/AIDS in Africa |
| WHO prequalified pharma units | India has the highest number globally |
The Semaglutide Case — Why It Matters
The patent expiry of Semaglutide is a microcosm of a broader pattern: blockbuster drug goes off-patent → Indian generic makers flood the market → prices crash → access improves. This pattern has played out with:
- Imatinib (Gleevec) — cancer drug; Indian generics reduced price from USD 70,000/year to USD 2,500/year
- Sofosbuvir (Sovaldi) — Hepatitis C cure; Gilead’s price USD 84,000 in the US; Indian generics: under USD 1,000
- COVID-19 vaccines — Serum Institute of India produced Covishield at scale for global distribution
The New Challenge with GLP-1 Drugs
Unlike previous generics, Semaglutide raises unique regulatory challenges:
- Dual-use drug — approved for both diabetes (medical) and weight loss (cosmetic/lifestyle)
- Social media-driven demand — influencers promote weight-loss drugs without medical context
- Injectable formulation — requires cold chain management and proper administration training
- Serious side effects — pancreatitis, gallbladder problems, thyroid tumour risk, severe GI issues
- Bioequivalence complexity — peptide-based drugs are harder to replicate than small-molecule generics
Regulatory Architecture — Strengths and Gaps
Current Framework
| Body | Role | Limitation |
|---|---|---|
| CDSCO (Central Drugs Standard Control Organisation) | Drug approval, clinical trial oversight, import regulation | Limited capacity for post-marketing surveillance; understaffed |
| State Drug Controllers | Manufacturing licences, retail pharmacy inspection | Fragmented; quality varies enormously across states |
| NPPA (National Pharmaceutical Pricing Authority) | Price control under DPCO for NLEM drugs | GLP-1 drugs not yet on NLEM — no price ceiling |
| Pharmacovigilance Programme of India (PvPI) | Adverse drug reaction monitoring | Reporting is voluntary; low awareness among practitioners |
Key Gaps Identified
- Post-marketing surveillance — India approves drugs efficiently but has weak systems for tracking adverse events after launch
- Prescription enforcement — Schedule H drugs require prescriptions, but pharmacies routinely sell without one
- Online pharmacy regulation — e-pharmacies operate in a regulatory grey zone; the e-Pharmacy Rules (draft since 2018) remain unnotified
- Bioequivalence standards — CDSCO guidelines exist but enforcement is inconsistent for complex biologics and peptide drugs
The NLEM Question
The National List of Essential Medicines (NLEM) determines which drugs are subject to price control under the Drug Price Control Order (DPCO):
| NLEM Detail | Information |
|---|---|
| Current version | NLEM 2022 (4th revision) |
| Total drugs listed | 384 |
| Price control mechanism | NPPA sets ceiling price for all NLEM drugs |
| GLP-1 drugs | Not currently on NLEM |
| Implication | Generic semaglutide prices are market-determined; no regulatory ceiling |
The editorial argues that including semaglutide in NLEM could ensure price control — but caution is needed as overly aggressive pricing could discourage Indian manufacturers.
TRIPS and India’s Patent Regime
India transitioned to a product patent regime in 2005 under TRIPS (Trade-Related Aspects of Intellectual Property Rights) compliance:
- Section 3(d) of the Indian Patents Act — prevents “evergreening” by denying patents to minor modifications of known substances unless they show significantly enhanced efficacy
- Compulsory licensing — Section 84 allows the government to issue licences for generic production if the patented drug is unaffordable or unavailable
- Natco Pharma v. Bayer (2012) — India’s first compulsory licence; for cancer drug Sorafenib (Nexavar)
UPSC Relevance
Prelims: CDSCO, NLEM 2022 (384 drugs), DPCO, NPPA, Section 3(d) of Indian Patents Act, Natco v. Bayer (2012, compulsory licence), TRIPS (2005 compliance), Schedule H drugs, PvPI. Mains GS2: Health regulation — role of CDSCO; drug pricing policy; e-pharmacy regulation gaps. Mains GS3: India as pharmacy of the world; pharmaceutical industry and IPR regime; TRIPS flexibilities.
📌 Facts Corner — Knowledgepedia
India Pharma — Key Data:
- India produces 20% of global generic medicines by volume
- 3rd largest by volume; 14th by value globally
- Supplies 200+ countries; ~40% of US generic demand
- WHO prequalified pharma units: highest number globally
- TRIPS product patent regime: since 2005
Regulatory Bodies:
- CDSCO: Central Drugs Standard Control Organisation (drug approval)
- NPPA: National Pharmaceutical Pricing Authority (price control)
- NLEM 2022: 384 drugs listed; GLP-1 drugs not included
- DPCO: Drug Price Control Order (ceiling prices for NLEM drugs)
- PvPI: Pharmacovigilance Programme of India
Key Legal Provisions:
- Section 3(d), Indian Patents Act: anti-evergreening provision
- Section 84: compulsory licensing
- Natco Pharma v. Bayer (2012): first compulsory licence in India (Sorafenib)
- Schedule H: prescription-only drug classification
Landmark Generic Drug Cases:
- Imatinib (Gleevec): USD 70,000 → USD 2,500/year (Indian generic)
- Sofosbuvir (Sovaldi): USD 84,000 → under USD 1,000 (Indian generic)
- Covishield: Serum Institute mass-produced COVID-19 vaccine
Sources: Indian Express, PIB